跳转至内容
Merck
  • Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

British journal of pharmacology (2014-06-26)
N Snelder, B A Ploeger, O Luttringer, D F Rigel, F Fu, M Beil, D R Stanski, M Danhof
摘要

Previously, a systems pharmacology model was developed characterizing drug effects on the interrelationship between mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (TPR). The present investigation aims to (i) extend the previously developed model by parsing CO into heart rate (HR) and stroke volume (SV) and (ii) evaluate if the mechanism of action (MoA) of new compounds can be elucidated using only HR and MAP measurements. Cardiovascular effects of eight drugs with diverse MoAs (amiloride, amlodipine, atropine, enalapril, fasudil, hydrochlorothiazide, prazosin and propranolol) were characterized in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats following single administrations of a range of doses. Rats were instrumented with ascending aortic flow probes and aortic catheters/radiotransmitters for continuous recording of MAP, HR and CO throughout the experiments. Data were analysed in conjunction with independent information on the time course of the drug concentration following a mechanism-based pharmacokinetic-pharmacodynamic modelling approach. The extended model, which quantified changes in TPR, HR and SV with negative feedback through MAP, adequately described the cardiovascular effects of the drugs while accounting for circadian variations and handling effects. A systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR was obtained in hypertensive and normotensive rats. This extended model can quantify dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using only HR and MAP measurements. Whether the model can be applied for compounds with a more complex MoA remains to be established.

材料
货号
品牌
产品描述

Sigma-Aldrich
阿托品 硫酸盐 一水合物, ≥97% (TLC), crystalline
Supelco
苯磺酸氨氯地平, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
苯磺酸氨氯地平, ≥98% (HPLC)
USP
阿托品盐酸盐标准液, United States Pharmacopeia (USP) Reference Standard
USP
苯磺酸氨氯地平(钙拮抗药), United States Pharmacopeia (USP) Reference Standard
Supelco
硫酸阿托品, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
马来酸依那普利, Pharmaceutical Secondary Standard; Certified Reference Material
USP
依那普利 马来酸盐, United States Pharmacopeia (USP) Reference Standard
苯磺酸氨氯地平, European Pharmacopoeia (EP) Reference Standard
氨氯地平, European Pharmacopoeia (EP) Reference Standard
依那普利, European Pharmacopoeia (EP) Reference Standard
阿托品 硫酸盐 一水合物, European Pharmacopoeia (EP) Reference Standard